<- Go Home
AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Market Cap
$10.5M
Volume
1.1M
Cash and Equivalents
$5.9M
EBITDA
-$16.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$64.80
52 Week Low
$0.38
Dividend
N/A
Price / Book Value
-0.53
Price / Earnings
-2.1K
Price / Tangible Book Value
-0.53
Enterprise Value
$22.6M
Enterprise Value / EBITDA
-1.40
Operating Income
-$16.5M
Return on Equity
0.01%
Return on Assets
-161.59
Cash and Short Term Investments
$5.9M
Debt
$18.0M
Equity
-$19.9M
Revenue
N/A
Unlevered FCF
-$6.0M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium